
Insmed Incorporated
- Jurisdiction
United States - LEI
529900Q55QAG41CCAC11 - ISIN
US4576693075 (INSM )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Read full profile
Fundamentals
- Net revenue
€339.56M - Gross margin
75.4% - EBIT
-€806.77M - EBIT margin
-237.6% - Net income
-€882.24M - Net margin
-259.8%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Flammer Martina M.D. | Chief Medical Officer |
|
|
|
|
Smith Michael Alexander | Chief Legal Officer |
|
|
|
|
SHAROKY MELVIN MD | N/A |
|
|
|
|
Adsett Roger | Chief Operating Officer |
|
|
|
|
Lewis William | Chair and CEO |
|
|
|
|
Congress transactions
Name | Transaction date | Value |
---|---|---|
Gilbert Cisneros | September 12, 2025 | $1.00K–$15.00K |
Gilbert Cisneros | August 14, 2025 | $1.00K–$15.00K |
Josh Gottheimer | July 16, 2025 | $1.00K–$15.00K |
Josh Gottheimer | May 14, 2025 | $1.00K–$15.00K |
Josh Gottheimer | July 9, 2024 | $1.00K–$15.00K |
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Stanley Druckenmiller |
|
|
|
Buy |
George Soros |
|
|
|
Sell |